Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Novartis Pharma LTA4H compound 3
- Development stage
- Preclinical
- Lead developer
- Novartis
01
Overview
Novartis Pharma LTA4H compound 3: sourced facts only. name: "Here, we describe the transformation of compound 2, a fragment-like hit, into the potent inhibitor of LTA4H 3." [PMID:38476002]; target: "Here, we describe the transformation of compound 2, a fragment-like hit, into the potent inhibitor of LTA4H 3." [PMID:38476002]; developer: "Global Discovery Chemistry, Biomedical Research, Novartis Pharma AG, 4002 Basel, Switzerland." [PMID:38476002]; stage: "Compound 3 exhibited exceptional selectivity and showed oral efficacy in a KRN passive serum-induced arthritis model in mice." [PMID:38476002]
02
Targets
LTA4H (Leukotriene A4 hydrolase)
Beyond the preview
Go deeper on Novartis Pharma LTA4H compound 3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novartis Pharma LTA4H compound 3.